ArticleInternational ophthalmology2026
Alpinia Oxyphylla-Shenqi Siwu Decoction protects against high glucose-induced retinal pigment epithelial cell injury involving the PI3K/AKT/mTOR pathway.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundDiabetic retinopathy (DR) is a leading cause of vision loss in working-age adults, and current treatments (anti-VEGF drugs, steroids, laser photocoagulation) mainly target late-stage microvascular complications while offering little for the neurodegeneration and neurovascular unit dysfunction that characterize early DR. Multi-component, multi-target traditional Chinese medicine compound decoctions are attractive candidates for early intervention. Here we investigated the protective effect and molecular mechanism of Alpinia Oxyphylla-Shenqi Siwu Decoction (AOSWSD) in a high glucose-induced ARPE-19 injury model of early DR.
methodsARPE-19 cells were exposed to 30 mmol/L glucose and treated with drug-containing rat serum obtained from rats gavaged with AOSWSD at low, middle and high doses (4.6, 9.2 and 18.4 g/kg/day of crude drug), with a matched normal-rat-serum control. Cell viability, migration, apoptosis, intracellular ROS, cytokine secretion, VEGFR2 immunofluorescence, p-AKT/AKT and p-mTOR/mTOR ratios, and mRNA levels of VEGFA, VEGFR2, HIF-1α, PIK3CA, AKT1, mTOR, Caspase-3, Bcl-2 and Bax were quantified by CCK-8 assay, scratch assay, flow cytometry, DCFH-DA staining, ELISA, immunofluorescence and RT-qPCR, respectively.
resultsUnder high-glucose exposure, AOSWSD-containing serum dose-dependently improved cell viability, restored migration, suppressed apoptosis, reduced intracellular ROS, and lowered the secretion of VEGFA, TNF-α and IL-6. Mechanistically, AOSWSD acted along a coordinated VEGFA/VEGFR2-PI3K/AKT/mTOR axis: it reduced secreted VEGFA and VEGFR2 protein at the upstream end, and lowered PIK3CA, AKT1 and mTOR transcripts together with the p-AKT/AKT and p-mTOR/mTOR ratios at the downstream end. Bcl-2, Bax and Caspase-3 expression and the Bax/Bcl-2 ratio were likewise restored towards control values.
conclusionAOSWSD protects ARPE-19 cells from high glucose-induced injury through simultaneous, dose-dependent modulation of oxidative stress, inflammation, apoptosis and angiogenic signaling, with the VEGFA/VEGFR2-PI3K/AKT/mTOR cascade acting as a principal molecular substrate. These results support AOSWSD as a candidate multi-target intervention for early-stage DR and provide a basis for further mechanistic, chemical and translational studies.
Indexed as
Identifiers
42720704What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.